After months of speculation about a rumored sale of its semiconductor unit, Agilent Technologies said this week that it would sell the segment to private equity firms Kohlberg Kravis Roberts and Silver Lake Partners for $2.66 billion.

By shedding a laggard that has been a drag on profitability, Agilent has enabled itself to focus more on growing its Life Sciences and Chemical Analysis group, which will be renamed the Bio-Analytical Measurement business. That segment has been one of the firm's more predictable and profitable businesses.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.